<div id="readability-page-1"><p>In a report released yesterday, Ben Hendrix from RBC Capital maintained a Buy rating on CVS Health, with a price target of <span id="expert-recommendation-target">$93.00</span>.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Hendrix is a 4-star analyst with an average return of <span>4.6%</span> and a 51.76% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as CVS Health, Brookdale Senior Living, and Select Medical.</p> <p>In addition to RBC Capital, CVS Health also received a Buy from J.P. Morgan’s Lisa Gill in a report issued on December 17. However, on December 12, Bernstein maintained a Hold rating on CVS Health (NYSE: CVS).</p></div>

<p>RBC Capital's Ben Hendrix maintained a Buy rating on CVS Health with a price target of $93.00. Hendrix, a 4-star analyst, has an average return of 4.6% and a 51.76% success rate. CVS Health also received a Buy rating from J.P. Morgan's Lisa Gill, while Bernstein maintained a Hold rating.</p>

RBC Capital Remains a Buy on CVS Health (CVS)